Bacitracin + colistin + hydrocortisone (combination preparation)

Generic name
Bacitracin + colistin + hydrocortisone (combination preparation)
Brand name
ATC Code
S02CA03

Bacitracin + colistin + hydrocortisone (combination preparation)

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Otorrhoea in middle ear inflammation with the presence of perforation or tube (see warning)
  • Auricular
    • 1 month up to 18 years
      • 5 drop(s)/dose 3 times daily.
      • Duration of treatment:

        Maximum 14 days

      • Directions for administration:

        Reconstitute the powder for eardrops with the accompanying solvent. The solution can be kept for 10 days. Shake vigorously before use.

      •  

         

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

The use of topical agents when the middle ear is open involves a (mild) risk of ototoxicity leading to high-frequency hearing loss and vestibulotoxicity that can cause balance problems. Ototoxicity is very rare in clinical settings, estimated at 0.01-0.03%, and is clearly less common than perceptual hearing loss due to a chronically secreting middle ear inflammation. Swollen middle ear mucosa as a result of chronically secreting middle ear inflammation also protects the middle ear against the ototoxic components of the ear drops.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Corticosteroids and antiinfectives in combination
S02CA03
S02CA06
S02CA07
S02CA07
S02CA03
S02CA03
S02CA04

References

  1. Mylanus E.A.M. et al, Standpunt nota \"Gebruik van oordruppels bij otitis media met trommelvliesperforatie en in operatieholtes\", 2006, Nederlandse Vereniging voor KNO en heelkunde van het hoof-halsgebied.
  2. Damoiseaux RAMJ et al., NHG-Standaard Otitis media acuta bij kinderen, Huisarts Wet, 2014, 57(12):, 648
  3. van Dongen et al., A trial of treatment for acute otorrhea in children with tympanostomy tubes, N Engl J Med, 2014, 370, 723-33

Changes

Therapeutic Drug Monitoring


Overdose